



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/70

Date: 31st January 2026

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

**Sub: Investor Presentation - Disclosure pursuant to Regulation 30 of SEBI
(Listing Obligations And Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In terms of Regulation 30 read with Para A of Part A of Schedule III to the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we hereby submit the updated Investor Presentation.

Request you to take the same on your record.

For, Sudarshan Pharma Industries Limited

Nirav Shah
Company Secretary & Compliance Officer



Encl: As above



Sudarshan Pharma Industries Limited

“Innovating Chemistry, Empowering Health”

INVESTOR PRESENTATION

E-mail : Compliance@sudarshanpharma.com

Website : www.sudarshanpharma.com

Contact No : CS Nirav Shah : 7700966328

Milestones



**2008-
2010**

- **2008** - Expanded market reach by importing high-quality raw materials and products.
- **2009** - Partnered with manufacturers to scale production and optimize costs.
- **2010** - Focused on new product development and market-driven innovation.

**2011-
2012**

- Generic formulations for institution supply, NGOs and wholesale market.
- Branded Generic formulations in Maharashtra.

**2013-
2014**

- Established our footprints in Gujarat, West Bengal, Chhattisgarh, and Uttar Pradesh.
- Introduced brands in New Drug Delivery System


**2015-
2016**

- Over 5,000 medical practitioners associated with SPIL.
- 7 own branded products introduced successfully in Vimac.

**2017-
2018**

- Manufacturing of Nutraceuticals.
- Brand Brilliance Award from Asian African leadership forum in Pharma.

Milestones




Existing Business Layout



Business Layout

The company is focusing on increasing manufacturing capabilities and has started **Vertical Integration** for expansion in the following segments:



As an organization built on the principles of upward integration within the pharmaceutical industry, we are committed to delivering high-quality products at affordable prices while consistently investing in in-house R&D.



Subsidiaries

SUDARSHAN PHARMA INDUSTRIES LIMITED

Wholly Owned Subsidiaries

Ratna Lifescience Private Limited

Products:

- Gemcitabine Hydrochloride
- 2,2-difluoro-2-deoxycytidine-3,5-dibenzoate (T9)
- Imatinib Mesylate
- Capecitabine Intermediate (Cap-5)

Life Science Chemical Private Limited

Products:

- Tannin extracts
- Solvents
- Dyestuffs
- Pigments

51% Ownership

Ishwari Healthcare Private Limited

Products:

- Polyglycolic Acid Sutures
- Polypropylene Mesh
- Infant Feeding Tube
- Thoracic Drainage Catheter



Subsidiaries

SUDARSHAN PHARMA INDUSTRIES LTD.

Wholly Owned Subsidiaries

Sudarshan Pharma Industries Private Limited, Singapore

The Company is engaged in wholesale trading activities across various categories, including basic industrial chemicals.

Sudarshan Pharma Lifescience Private Limited

Products:

- Pharmaceuticals
- Antibiotics, Drugs, Medicines
- Biological Products

Cibachem General Trading LLC, Dubai

The Company is in the business of trading activities of all types of goods and ancillary insurance activities.

70% Ownership

Sudarshan Maven Pharma Private Limited

Products:


- Pharmaceuticals,
- API & Intermediates,
- Antibiotics, Drugs, Medicines,
- Biological neutraceuticals.

SUDARSHAN PHARMA – SRIGEN NEW MANUFACTURING UNIT



Hyderabad Unit

Hyderabad Unit is bulk drug & intermediate manufacturing unit. It has developed about 50 potential API Key starting materials and also having an outstanding commercial technology. Few key starting materials hold Patent rights and those intermediates were currently in manufacturing commercial scale with proper regulatory documentation support. The said unit has a reactor capacity in its manufacturing facility and it will be executed at its contract manufacturing GMP facility located at Hyderabad as Advanced API's Technology Transfers (TT).



Key value Proposition



Why Invest in Sudarshan Pharma Industries Limited

The Company delivers trusted pharmaceutical solutions through a strong focus on quality, compliance and long-term partnerships. With a robust portfolio of Specialty Chemicals, Advanced Intermediates, Active Pharmaceutical Ingredients & excipients, we consistently meet IP, BP and USP standards, ensuring reliability for regulated markets.

Our strength lies in ethical operations, transparent documentation, and customer protection, backed by experienced industry professionals and efficient supply chain management. We prioritize on-time delivery, technical support and regulatory readiness, enabling our partners to scale with confidence.

Driven by a clear growth vision, the Company is committed to sustainable expansion, market diversification and value creation, making us a dependable and future-ready partner for investors and customers alike.



Market Pain Point & Opportunity We Address



The global pharmaceutical supply chain faces a critical challenge due to high dependency on China for raw material of specialty chemicals, intermediates and excipients. This dependency exposes manufacturers to price volatility, inconsistent supply, geopolitical risks, tariff uncertainties, and regulatory disruptions, impacting cost stability and production timelines. Frequent rate fluctuations, logistics disruptions, and changing trade policies have created an urgent need for reliable, compliant, and diversified sourcing alternatives for regulated markets.

Market Gap:

Over-dependence on China leading to price volatility, supply uncertainty, and tariff risks.



Our Value:

A compliant, reliable, India-based alternative delivering quality, stability, and long-term supply assurance.

Our Solution – The Sudarshan Advantage



Sudarshan Pharma Industries addresses this gap by offering a trusted India-based alternative to China. We deliver high-quality Specialty Chemicals, Advanced Intermediates, APIs, and Excipients manufactured and sourced in compliance with IP, BP, and USP standards, ensuring consistency, transparency, and long-term supply security.



- ✓ Cost stability and predictable pricing
- ✓ Supply chain resilience
- ✓ Tariff and geopolitical risk mitigation
- ✓ Regulatory-ready documentation for global markets

How Our Products & Services Solve the Market Problem




Problem: China dependency → **Solution:** India-based compliant manufacturing

Result: Stable, secure & future-ready pharma supply chain

FOCUSED MARKET




New Export Avenues



New Clintele



Major African Markets





Lead Management



Mr. Hemal V. Mehta | Chairman & Managing Director

Hemal Mehta, Founder-Promoter and Chairman & Managing Director of Sudarshan Pharma Industries Ltd., brings 26 years of extensive experience in the pharmaceutical and chemical manufacturing industry. He is recognized for his expertise in innovation and technology, driving the development of advanced and innovative products aimed at addressing incurable diseases



Mr. Sachin V. Mehta | Joint Managing Director & CFO

Sachin Mehta, Founder-Promoter, Joint Managing Director & Chief Financial Officer of Sudarshan Pharma Industries Ltd., excels in sourcing specialty chemicals, leading R&D initiatives, developing import substitutes and driving business excellence. His strategic leadership plays a pivotal role in the Company's growth and innovation

Board of Directors



Vijay Ojha | Independent Director



Dr. Vijay Ojha is a result oriented Biotech Professional with General Management knowledge having about 29+ years of Industrial experience in R&D, Project and Production. Comprehensive knowledge of Microbiology, Fermentation, Downstream Purification and Analytical. Worked on different Primary and Secondary metabolites.

Jaya Singhania | Independent Director



Registered as an Independent Director with the databank of IICA. She has authored numerous write-ups on corporate & allied laws. She is a staunch believer in creating leaders as the knowledge has to be passed down and can't be retained. Recently, she has been listed as one of the Top Best Ten Women Legal Consultants in India 2021 by Women Entrepreneur Magazine.

Rushabh Patil | Independent Director



Adv. Rushabh Prashant Patil is a Practicing Independent Advocate in the Bombay High Court & District courts with a demonstrated history of working in the legal fraternity. He has acted as an advisory for several clients on corporate and commercial transactions including strategic alliance and routine advisory on civil matters.

Anil Ghoghare | Non-Executive Director



Presently working as Advisor, Director in various Pharmaceutical companies and is the Promoter of M/S. Pharma-In-Future Technology & GMP / Regulatory consultant for design of plant, technology transfers, regulatory support. He has 37+ years of experience. His vision includes excellence in Technology, Facility design and GMP work culture through people, technology & teamwork in pharmaceutical field.

Senior Key Personnel



1. Mr. Raju Sanghvi

Senior Accountant

7. Mrs. Namrata Mehta

Vice President (Sales)

2. Mr. Santosh Thakur

Import Manger

8. Mr. Bhavesh Kanakia

Vice President - Purchase

3. Mr. Shrinivas Patil

Sales Manager

9. Mr. Amit Yadav

Finance Manager

4. Mrs. Shrishti Mayekar

Sales Head

10. Mrs. Snehal Kate

Banking Manager

5. Mrs. Priti Muni

President (Sales)

11. Ms. Sonam Mishra

Account Manager

6. Mrs. Devangi Mehta

Vice President (Sales)

12. Mr. Amit Mehta

Purchase Manager

Senior Key Personnel



13. Mr. Milan Shah

Purchase Manager

19. Mr. Mayank Vyas

President (Business Development Manager)

14. Mr. Nirav Shah

CS & Compliance Officer

20. Mr. Vishal Bhosale

Production Head (Jejuri)

15. Mr. Vasantrai Mehta

President (Admin)

21. Mr. Kuldeep Devgude

QC (Jejuri)

16. Mr. Jatin Mehta

Vice President (Admin)

22. Mr. G P Ankaiah

Production head (Hyderabad Unit)

17. Mrs. Darshana Mehta

Vice President (Admin)

23. Mr. Siva Sankarrao Gollu

QA (Hyderabad Unit)

18. Mr. Rahul Pandey

President (Business Operations & Development)

24. Mr. Anjaneya Raju Ponnamanda

QC (Hyderabad Unit)



Senior Consultants

Dr. Vishwas Joshi

Dr. S Venkat Rao

Dr. Lanka Rao

Mr. Dhrumit Patel

Dr. Rajesh Patil

Dr. Purshotam Madupu

OUR ESTEEMED CLIENTELE



Consolidated Profit & Loss Account (Rs. in Crores)




PARTICULARS	QUARTER			ANNUAL
	31.12.2025	30.09.2025	30.06.2025	31.03.2025
INCOME				
Revenue from Operations	168.01	168.87	145.26	505.04
Other Income	1.52	1.86	1.21	2.66
Total Income (I)	169.52	170.73	146.47	507.69
EXPENSES				
Cost of Materials Consumed	13.21	0.31	5.42	8.93
Purchase of Stock-in-Trade	148.81	171.18	139.53	485.18
Depreciation and Amortization Expenses	0.91	0.90	0.88	2.81
Other Expenses	7.36	5.57	3.42	21.40
Total Expenses (II)	164.33	166.50	141.06	484.86
Exceptional items	-	-	-	2.82
Profit before extraordinary items and tax	5.20	4.23	5.41	20.02
Extraordinary items	-	-	-	-
Profit before Tax	5.20	4.23	5.41	20.02
Total Tax Expenses	1.05	0.36	1.46	5.05
Profit after Tax	4.15	3.87	3.96	14.97
Earning per equity share:				
Basic EPS	0.18	0.16	0.16	0.62
Diluted EPS	0.18	0.16	0.16	0.62

Financial Metrics: Focus on Margin Optimization and Profit Growth




Revenue from Operations


INR in Crs



Operating EBITDA & EBITDA Margin (%)



PAT & PAT Margin (%)




The Company is continuously focusing on increase in exports and manufacturing sales and even working on to maximize its profit margin on resale of API in local markets, therefore, there is substantial growth in EBITDA margin in FY25 and consequently, the Company has achieved substantial growth in PAT for the same period.


FINANCIAL PERFORMANCE :




Revenue from Operations (Rs Cr)



EBITDA (Rs Cr)




PAT (Rs Cr)




ROCE (%)



ROE (%)



Debt to Equity (x)



Historical Consolidated Profit & Loss Statement (Rs. In Crores)



PARTICULARS	31.03.2025	31.03.2024	31.03.2023
INCOME			
Revenue from Operations	505.05	463.54	461.33
Other Income	2.52	2.61	1.12
Total Income (I)	507.57	466.15	462.45
EXPENSES			
Cost of Materials Consumed	8.93	6.31	0.32
Purchase of Stock-in-Trade	485.18	424.04	457.25
Depreciation and Amortization Expenses	2.22	1.24	0.91
Other Expenses	20.48	14.61	12.72
Total Expenses (II)	483.12	450.92	452.95
Exceptional items	2.82	-	-
Profit before extraordinary items and tax	21.63	15.23	9.50
Extraordinary items	-	-	-
Profit before Tax	21.63	15.23	9.50
Total Tax Expenses	5.75	3.77	2.46
Profit after Tax	15.88	11.46	7.04
Earning per equity share			
Basic EPS	0.66	4.76	5.48
Diluted EPS	0.66	4.76	5.48

Historical Consolidated Balance Sheet (Rs. in Crores)



PARTICULARS	31.03.2025	31.03.2024	31.03.2023
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
Share Capital	24.07	24.07	24.07
Reserves and Surplus	103.52	87.64	76.91
(2) Non-Current Liabilities			
Long-Term Borrowings	10.46	10.49	12.79
Other Long Term Liabilities	0.49	0.09	0.06
Deferred Tax Liabilities (Net)	0.31	0.02	0.18
(3) Current Liabilities			
Short-Term Borrowings	160.27	94.35	21.32
Trade Payables	91.83	56.72	91.89
Other Current Liabilities	2.14	7.03	4.56
Short Term Provisions	5.50	2.74	0.71
Total Equity & Liabilities	402.41	283.13	232.48
II. ASSETS			
(1) Non-Current Assets			
Property, Plant and Equipment's & Intangible Assets	29.91	27.38	19.90
Non-Current Investments	28.84	12.34	12.34
Long Term Loans and Advances	4.56	1.83	1.62
Other Non-Current Assets	4.25	-	-
(2) Current Assets			
Current Investments	1.50	1.50	-
Inventories	140.48	85.74	74.57
Trade Receivables	160.16	122.55	81.51
Cash and Cash Equivalents	0.55	0.14	11.72
Short Term Loans & Advances	4.61	-	10.87
Other Current Assets	27.54	31.64	19.96
Total Assets	402.41	283.13	232.48



Thank you
